Albany, NY -- (SBWIRE) -- 10/11/2017 -- Peptic ulcer disease represents a group of ulcerative disorders such as gastritis, gastric ulcers, and duodenal ulcers or gastroesophageal reflux disease (GERD). Treatment of peptic ulcers is achieved through drugs such as proton pump inhibitors (PPI), potassium-competitive acid blockers (P-CAB), antacid, H2-antagonist, antibiotics, and ulcer protective drugs such as sucralfate. Increasing usage of non-steroidal anti-inflammatory drugs such as aspirin due to increasing inflammatory conditions is the major factor driving the growth of the global peptic ulcer drugs market. However, side effects of long-term use of PPIs, changing government policies, loss of market exclusivity of a majority of peptic ulcer drugs, and limited R&D efforts in the field of peptic ulcer drugs are factors expected to hamper the growth of peptic ulcer drugs market, globally.
Click to get sample PDF with TOC: https://www.researchmoz.us/enquiry.php?type=S&repid=1287192
The peptic ulcer drugs market is segmented as follows:
- By Product Type
- By Disease Indication
- By Distribution Channels
- By Region
This report covers the global peptic ulcer drugs market performance in terms of revenue contribution. The report includes key trends, drivers, restraints, and opportunities influencing the growth of the global peptic ulcer drugs market over the forecast period. Impact analysis of key growth drivers and restraints, based on the weighted average model, are included to provide clients with crystal clear decision-making insights.
Based on product type, the global peptic ulcer drugs market is segmented into proton pump inhibitors (PPI), potassium-competitive acid blockers (P-CAB), antacids, ulcer protective drugs, H2-antagonists, and antibiotics. The PPIs segment is expected to remain the dominant segment in terms of value during the forecast period.
By disease indication, the global peptic ulcer drugs market is segmented as gastritis, gastric ulcer, duodenal ulcer or gastroesophageal reflux disease (GERD). GERD segment is expected to dominate in terms of market share contribution, accounting for the maximum share of the overall market by 2022 end; whereas revenue from gastric ulcer segment is projected to expand at highest CAGR of during the forecast period.
By region, the market in North America is expected to lead in the global peptic ulcer drugs market. In 2014, North America and Europe collectively accounted for 67% share of overall marker revenue. Asia Pacific market accounted for 22% share in global peptic ulcer drugs market and is expected to gain significant market share over the forecast period, due to increasing recurrence of peptic ulcer disease. The MEA market is expected to witness sluggish growth during the forecast period partly due to low accessibility to peptic ulcer drugs in the region.
Key market players covered in this report include:
- Daewoong Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited.
- Pfizer Inc.
- Abbott Laboratories.
- AstraZeneca Plc.
- Cadila Healthcare Ltd.
- Boehringer Ingelheim GmbH.
- Eisai Co. Ltd.
- Yuhan Corporation.
- GlaxoSmithKline Pharmaceuticals Ltd.
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Albany NY - 12207
Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at: http://bit.ly/1TBmnVG